Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

July 16, 2026

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders

Concurrent $132 million private investment with participation from leading life sciences investors and Mirador Therapeutics

Kira out-licenses KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist, to Mirador Therapeutics, for $12 million upon signing and potential development and sales milestone payments

Combined financing and transactions expected to fund combined company operations through the second half of 2028, including multiple clinical milestones

REDWOOD CITY, Calif. and CAMBRIDGE, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper" or the "Company"), today announced that Jasper has completed the acquisition of Kira Pharmaceuticals ("Kira"), a former Cayman limited company that was engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock transaction (together, the "Combined Company"). Concurrent with the acquisition, Jasper entered into a securities purchase agreement for the sale of non-voting convertible preferred stock (the "Preferred Stock") in a private placement transaction co-led by Affinity Asset Advisors, LLC and Ikarian Capital LLC with participation from Columbia Threadneedle Investments, Sirenia Capital Management LP, Brahma Capital, Balyasny Asset Management, SilverArc Capital, Squadron Capital Management, Nazare Partners LP, and Mirador Therapeutics as well as other leading life sciences investors and certain members of Kira management. The private placement is expected to result in total gross proceeds of approximately $132 million. The proceeds from the private placement will be used to fund development of the Combined Company's pipeline through the second half of 2028. The Combined Company will focus on advancing a consolidated pipeline of potential best-in-class innovative therapies for immunologically-driven disorders, including KP-104, a potential best-in-class dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and high unmet need nephrology disorders, briquilimab, an anti-KIT antibody with broad therapeutic utility across multiple transplant and immunologic indications, and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The Combined Company will continue to trade on Nasdaq under the ticker symbol "JSPR."

The Combined Company's cash and cash equivalents balance at closing, including the proceeds from the private placement and out-licensing transaction, but excluding any milestone payments, is anticipated to fund the Combined Company's operations through the second half of 2028 and provide runway through key clinical milestones, including KP-104 Phase 2 results in potential renal disorders, an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to support the potential initiation of a Phase 3 study evaluating KP-104 for PNH, the advancement of briquilimab in Severe Combined Immunodeficiency (SCID) to a pre-Biologics License Application (BLA) meeting, and first-in-human data for KP-701.

"We are pleased to announce this transaction with Kira following a thorough evaluation of strategic alternatives. Kira has built a truly differentiated complement portfolio that includes dual MOA beyond single-pathway agents and long-acting complement inhibitors, reflecting the quality of their science and the deep expertise of their team. We are excited by the robust pipeline that this transaction creates, and are looking forward to advancing these important medicines for patients," said Jeet Mahal, President and Chief Executive Officer of Jasper.

"Today's announcement marks a transformative step for the product candidates that Kira has developed. As we advance as part of Jasper, our mission is to develop biologic agents designed to improve outcomes in patients suffering from numerous immunologically-driven disorders. We will leverage the Combined Company's management team with deep expertise in antibody drug development and support from leading life science investors," said Patrick Crutcher, MSc, formerly the Chairman of the Board of Kira. "In conjunction, the out-licensing of KP-301 and KP-402 to Mirador and their highly experienced team allows for the Combined Company to rapidly accelerate its potentially best-in-class portfolio toward significant value creating milestones, while also allowing for the development of these potentially best-in-class assets. With this strengthened foundation, and the synergies between our team and the Jasper team, we believe the Combined Company is exceptionally well-positioned to progress our portfolio of biologic agents targeting high-value immunology targets. We are now focused on executing on multiple upcoming clinical milestones that have the potential to impact patients in need of better therapeutic options."

Transaction Highlights:

- **Consolidated innovative pipeline of high-value immunology targets:** The Combined Company plans to advance a consolidated pipeline across immunologically-driven disorders, including:
  - KP-104 (Vensobafusp alfa): a Phase 2/3 ready, potentially best-in-disease, bifunctional biologic targeting both the alternative and terminal pathways within the complement cascade
    - The Combined Company expects to report interim data from Stage 1 of the ongoing Phase 2 basket trial in rare renal indications in the fourth quarter of 2026, and updated data in the second quarter of 2027. Additionally, the Combined Company plans to report interim data from Stage 2 of the study in the second quarter of 2027.
    - Based on previous, positive data in treatment-naïve PNH, the Combined Company is planning for an end-of-Phase 2 meeting with the FDA and plans to announce next steps in the first half of 2027.
    - By the end of the year, the Combined Company anticipates that it will announce a new indication for

KP-104.
    - Briquilimab: a late-stage, potentially best-in-class anti-KIT antibody
        - Following positive, long-term data in SCID, the Combined Company is progressing its efforts towards a pre-BLA meeting with the FDA and expects to announce next steps in the first quarter of 2027.
        - The Combined Company also continues to assess the mast-cell mediated disease landscape and will provide an update on its anticipated clinical development in the second half of this year.
    - KP-701: a preclinical, B-cell receptor targeted therapy
        - In the first quarter of 2027, the Combined Company expects to file a clinical trial application (CTA) or an investigational new drug (IND) for Phase 1 testing and plans to report first in human data in the third quarter of 2027.
- **KP-301 and KP-402 out-licensing deal:** Kira has out-licensed KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist to Mirador Therapeutics. This transaction will provide a $12 million upfront payment and potential development and sales milestone payments. Mirador brings deep experience across drug development and translational immunology that supports the advancement of these potential best-in-class molecules. Out-licensing these assets allows the Combined Company to focus its resources on its current portfolio of high-value immunology targets.
- **Management and Organization:** The Combined Company will be comprised of a highly experienced team, including:
    - Jeet Mahal, President and Chief Executive Officer;
    - Herb Cross, Chief Financial Officer;
    - Greg Keenan, M.D., Chief Medical Officer;
    - Matthew E. Ros, Chief Operating Officer;
    - Wenru Song, M.D., Ph.D., Executive Vice President and Head of R&D;
    - In conjunction with the transaction, the Board of Directors of the Combined Company will be comprised of Patrick Crutcher, MSc, Jeet Mahal, Thomas Wiggans, Judith Shizuru, M.D., Ph.D., Svetlana Lucas, Ph.D., and Kurt von Emster.
- **Cash Runway:** Pro-forma cash for the Combined Company is expected to fund operations of the Combined Company, as currently intended to be carried out, through multiple anticipated clinical milestones through the second half of 2028.

About the Transaction

The acquisition of Kira was structured as a stock-for-stock transaction whereby all of Kira's outstanding equity interests were exchanged for a combination of shares of Jasper common stock and Preferred Stock. Subject to approval by Jasper's stockholders in accordance with Nasdaq listing rules, each share of Preferred Stock will automatically convert into 61 shares of Jasper common stock, subject to certain beneficial ownership limitations. Concurrently with the acquisition of Kira, Jasper entered into a securities purchase agreement pursuant to which Jasper agreed to sell approximately 4.7 million shares of Preferred Stock for an aggregate purchase price of approximately $132 million. The private placement is expected to close on July 20, 2026.

In connection with the acquisition of Kira, each holder of Jasper common stock as of immediately before the closing of the transaction will be entitled to a non-transferrable contingent value right ("CVR"). Holders of the CVR will be entitled to receive an aggregate of $30 million in payments related to Jasper obtaining a priority review voucher ("PRV") by December 31, 2028 for briquilimab, provided that such payments shall only be due upon the monetization of the CVR or in the event of an acquisition of the Combined Company subsequent to the receipt of the PRV.

The acquisition was approved by the Board of Directors of Jasper and the Board of Directors and shareholders of Kira. The approval of Jasper's stockholders is required, among other things, under the terms of the Preferred Stock in order for the Preferred Stock to be converted into shares of Jasper common stock, and Jasper is required to hold a stockholder meeting for such vote. As a result of the transactions, equityholders of Jasper immediately prior to the acquisition will own approximately 6.68% of Jasper's common stock, equityholders of Kira immediately prior to the acquisition will own approximately 49.86% of Jasper's common stock and investors in the private placement financing will own approximately 43.46% of Jasper's common stock, in each case, calculated on a fully-diluted, as-converted-to-common-basis (and without giving effect to any beneficial ownership limitations), and based on the implied equity values of Jasper and Kira. On an as-converted basis and after accounting for these transactions, the total number of shares of Jasper common stock outstanding would be approximately 653.6 million immediately after the closing of the transactions.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Advisors

Piper Sandler & Co. served as the exclusive financial advisor and DLA Piper LLP (US) served as legal counsel to Kira. H.C. Wainwright & Co. served as financial advisor and Paul Hastings LLP served as legal counsel to Jasper. Piper Sandler & Co. served as lead placement agent and LifeSci Capital LLC served as co-placement agent for the concurrent financing.

About Jasper

Jasper is a clinical-stage biotechnology company focused on the development of briquilimab, a targeted anti-KIT monoclonal antibody with a demonstrated safety and efficacy profile in patients and healthy volunteers in multiple chronic immunological and inflammatory diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the KIT receptor, inhibiting an essential survival signal for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated positive clinical outcomes both as a

conditioning agent for stem cell transplant in SCID and Fanconi anemia, and via mast cell depletion in diseases such as chronic urticarias and allergic asthma. For more information, please visit us at www.jaspertx.com.

Forward-Looking Statements

Certain statements contained in this press release are or may be considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate,” “potential,” “projected” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. Jasper cautions that these statements are based upon the current beliefs and expectations of Jasper’s management and are subject to significant risks, uncertainties and assumptions, including, without limitation, risks related to the market price of Jasper’s common stock relative to the value suggested by the exchange ratio in connection with the merger; unexpected costs, charges or expenses resulting from the merger; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger; the uncertainties associated with the Combined Company’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; risks related to the inability of the Combined Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks associated with the possible failure to realize certain anticipated benefits of the merger, including with respect to future financial and operating results; the risk that the private placement is not consummated; the possibility that holders of CVRs may never receive any proceeds; risks related to the possibility that Jasper’s shareholders may not approve the conversion of the Preferred Stock, and such additional risks and uncertainties contained in the “Risk Factors” section of Jasper’s Annual Reports on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that Jasper has subsequently filed or may subsequently file with the SEC. Statements regarding future actions, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or approval and commercial launch and sales results (if any) of the Combined Company’s formulations and product candidates and regulatory filings related to the same, financial projections and targets, business strategy, plans and objectives for future operations, statements regarding the Combined Company and its operations and prospects, may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. There is no obligation to update publicly or revise any forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or to changes in the Combined Company’s expectations, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws.

For Investor Inquiries

Argot Partners (investors and media)
kira@argotpartners.com

Jasper Therapeutics

Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertx.com

Media:
media@jaspertx.com

Jasper Therapeutics 宣布与 Kira Pharmaceuticals （科越医药）合并

合并后公司将推进旗下生物制剂产品组合,旨在改善多种免疫相关疾病患者的治疗结果

同期完成 1.32 亿美元私募融资,多家知名生命科学投资者及 Mirador Therapeutics 参与其中

Kira 将其长效抗 C5a 单克隆抗体 KP-301 及小分子 C5a 受体拮抗剂 KP-402 对外授权给 Mirador Therapeutics,签约即获得 1200 万美元付款,并有望获得后续开发和销售里程碑付款

本次融资及相关交易预计将为合并后公司提供资金,支持其运营至 2028 年下半年,涵盖多个临床里程碑节点

加利福尼亚州红木城和马萨诸塞州剑桥,2026 年 7 月 16 日——Jasper Therapeutics, Inc.(纳斯达克股票代码:JSPR,以下简称“Jasper”或“公司”)今日宣布,公司已完成对 Kira Pharmaceuticals(“Kira”)的收购。Kira 原为一家开曼群岛有限公司,专注于设计用于治疗免疫介导疾病的补体疗法。此次交易为全股票交易(合并后的公司统称“合并后公司”)。与本次收购同时,Jasper 签署了一份证券购买协议,拟通过私募方式发行无投票权可转换优先股(“优先股”),本次私募由 Affinity Asset Advisors, LLC 与 Ikarian Capital LLC 共同牵头,参与方包括 Columbia Threadneedle Investments、Sirenia Capital Management LP、Brahma Capital、Balyasny Asset Management、SilverArc Capital、Squadron Capital Management、Nazare Partners LP 以及 Mirador Therapeutics,此外还有其他知名生命科学投资者及部分 Kira 管理层成员。本次私募预计将带来总额约 1.32 亿美元的毛募集资金。私募所得资金将用于支持合并后公司管线的开发,资金可支撑至 2028 年下半年。合并后公司将专注于推进针对免疫相关疾病的整合管线,打造潜在同类最优的创新疗法,包括:KP-104,一款潜在同类最优的双重补体抑制剂,用于治疗阵发性睡眠性血红蛋白尿症(PNH)及高度未满足需求的肾病;briquilimab,一款抗 KIT 抗体,在多个移植及免疫适应症领域具有广泛的治疗潜力;以及 KP-701,一款新型双重作用抗 CD79BxCD32B 单克隆抗体(mAb),用于治疗自身抗体介导性疾病。合并后公司将继续以股票代码“JSPR”在纳斯达克交易。

合并后公司在交易完成时的现金及现金等价物余额(包括私募融资及对外授权交易所得款项,但不包括任何里程碑付款)预计将支持公司运营至 2028 年下半年,并为多个关键临床里程碑提供资金保障,包括:KP-104 在潜在肾病适应症中的 2 期数据结果;与美国食品药品监督管理局(FDA)举行 PNH 临床 2 期结束会议,以支持启动评估 KP-104 治疗 PNH 的临床 3 期研究;推进 briquilimab 在重症联合免疫缺陷病(SCID)适应症中的开发至生物制品许可申请(BLA)前会议阶段;以及 KP-701 的首次人体试验数据。

Jasper 总裁兼首席执行官 Jeet Mahal 表示:“在对各项战略方案进行了充分评估之后,我们很高兴宣布与 Kira 达成此项交易。Kira 打造了一个真正差异化的补体产品组合,涵盖了超越单一通路

药物的双重作用机制以及长效补体抑制剂,充分体现了其科学实力和团队的深厚专业积淀。我们对本次交易所形成的强大管线感到振奋,并期待为患者推进这些重要药物的研发。”

Kira 前董事会主席、理学硕士 Patrick Crutcher 表示:“今天的公告标志着 Kira 所研发的候选产品迈出了具有变革意义的一步。作为 Jasper 的一部分继续前行,我们的使命是开发生物制剂,以改善众多免疫相关疾病患者的治疗结果。我们将借助合并后公司管理团队在抗体药物开发方面的深厚专业积累,以及来自知名生命科学投资者的支持。”“同时,将 KP-301 和 KP-402 对外授权给经验丰富的 Mirador 团队,使合并后公司能够快速推进其潜在同类最优产品组合,朝着重要的价值创造里程碑迈进,同时也有助于这些潜在同类最优资产的开发。凭借这一更加稳固的基础,以及我们团队与 Jasper 团队之间的协同效应,我们相信合并后公司将处于极为有利的位置,推进其针对高价值免疫靶点的生物制剂产品组合。目前,我们正专注于执行多项即将到来的临床里程碑,这些里程碑有望为亟需更优治疗选择的患者带来切实影响。”

交易要点:

- 整合后的高价值免疫靶点创新管线:合并后公司计划推进覆盖免疫相关疾病领域的整合管线,包括:
    - KP-104(Vensobafusp alfa):一款已具备进入临床 2/3 期研究条件、潜在同类疾病最优的双功能生物制剂,同时靶向补体级联反应中的旁路途径和终末途径
        - 合并后公司预计将于 2026 年第四季度公布正在进行的罕见肾病适应症 2 期篮式试验第一阶段的中期数据,并于 2027 年第二季度公布更新数据。此外,合并后公司计划于 2027 年第二季度公布该研究第二阶段的中期数据。
        - 基于此前在初治 PNH 患者中获得的积极数据,合并后公司正计划与 FDA 召开 PNH 临床 2 期结束会议,并计划于 2027 年上半年公布后续计划。
        - 合并后公司预计将于年底前公布 KP-104 的一项新适应症。
    - Briquilimab:一款处于后期开发阶段、潜在同类最优的抗 KIT 抗体
        - 基于在 SCID 适应症中获得的积极长期数据,合并后公司正推进与 FDA 召开 BLA 前会议的相关工作,并预计于 2027 年第一季度公布后续计划。
        - 合并后公司还将继续评估肥大细胞介导疾病领域的相关情况,并将于今年下半年就其预期的临床开发计划提供最新进展。
    - KP-701:一款处于临床前阶段、靶向 B 细胞受体的疗法
        - 合并后公司预计将于 2027 年第一季度提交临床试验申请(CTA)或研究性新药申请(IND),以开展 1 期测试,并计划于 2027 年第三季度公布首次人体试验数据。

- KP-301 与 KP-402 对外授权交易:Kira 已将其长效抗 C5a 单克隆抗体 KP-301 及小分子 C5a 受体拮抗剂 KP-402 对外授权给 Mirador Therapeutics。本次交易将带来 1200 万美元的首付款,以及潜在的开发和销售里程碑付款。Mirador 在药物开发和转化免疫学领域拥有深厚经验,将有助于推进这些潜在同类最优分子的开发。将这些资产对外授权,使合并后公司能够将资源集中于当前的高价值免疫靶点产品组合。
- 管理团队与组织架构:合并后公司将由一支经验丰富的团队组成,包括:
    - Jeet Mahal,总裁兼首席执行官;
    - Herb Cross,首席财务官;
    - Greg Keenan 医学博士,首席医学官;
    - Matthew E. Ros,首席运营官;
    - Wenru Song 医学博士、哲学博士,执行副总裁兼研发负责人;
    - 结合本次交易,合并后公司的董事会将由 Patrick Crutcher(理学硕士)、Jeet Mahal、Thomas Wiggans、Judith Shizuru(医学博士、哲学博士)、Svetlana Lucas(哲学博士)及 Kurt von Emster 组成。
- 现金储备:合并后公司的备考现金预计将支持公司按当前计划开展运营,资金可覆盖至 2028 年下半年的多个预期临床里程碑。

关于本次交易

本次对 Kira 的收购构建为股票换股票交易,Kira 全部已发行流通股权益按比例换取 Jasper 普通股及优先股的组合。根据纳斯达克上市规则,在获得 Jasper 股东批准后,每股优先股将自动转换为 61 股 Jasper 普通股,但须遵守特定实益所有权限制。与收购 Kira 同时,Jasper 签署了一份证券购买协议,约定 Jasper 将出售约 470 万股优先股,总购买价约为 1.32 亿美元。本次私募预计将于 2026 年 7 月 20 日完成交割。

就本次收购 Kira 而言,在交易完成前持有 Jasper 普通股的每位股东将获得一项不可转让的或有价值权(“CVR”)。若 Jasper 于 2028 年 12 月 31 日前就 briquilimab 获得优先审评凭证(“PRV”),CVR 持有人将有权获得合计 3000 万美元的相关付款,但该等付款仅在 CVR 变现,或在获得 PRV 后合并后公司被收购的情况下方需支付。

本次收购已获得 Jasper 董事会以及 Kira 董事会和股东的批准。根据优先股条款等相关规定,优先股转换为 Jasper 普通股尚需获得 Jasper 股东批准,为此 Jasper 须召开股东大会进行表决。交易完成后,按完全稀释、全部转换为普通股的基础计算(且不考虑任何实益所有权限制),并基于 Jasper 与 Kira 的隐含股权价值,收购前 Jasper 股权持有人将持有 Jasper 普通股约 6.68%,收购前

Kira 股权持有人将持有约 49.86%,私募融资投资者将持有约 43.46%。按转换后计算,并计入上述交易影响后,交易完成后 Jasper 流通在外普通股总数预计约为 6.536 亿股。

本新闻稿不构成出售任何证券的要约或购买任何证券要约的邀请,亦不构成在任何要约、邀请或出售属违法的州或其他司法管辖区内,在根据该州或其他司法管辖区证券法完成注册或取得资格之前进行任何该等证券的出售。

顾问团队

Piper Sandler & Co.担任 Kira 的独家财务顾问,DLA Piper LLP(US)担任其法律顾问。H.C. Wainwright & Co.担任 Jasper 的财务顾问,Paul Hastings LLP 担任其法律顾问。本次同期融资由 Piper Sandler & Co.担任牵头配售代理,LifeSci Capital LLC 担任联合配售代理。

关于 Jasper

Jasper 是一家临床阶段生物技术公司,专注于开发 briquilimab,这是一款靶向抗 KIT 单克隆抗体,已在多种慢性免疫性及炎症性疾病患者和健康志愿者中展现出良好的安全性和有效性。Briquilimab 是一款靶向性去糖基化单克隆抗体,可阻断干细胞因子与 KIT 受体的结合,从而抑制肥大细胞的关键生存信号以及造血干细胞的维持信号。briquilimab 介导的 KIT 抑制已在多个方面展现出积极的临床结果,包括作为 SCID 和范可尼贫血患者干细胞移植的预处理药物,以及通过清除肥大细胞用于治疗慢性荨麻疹和过敏性哮喘等疾病。欲了解更多信息,请访问我们的网站:www.jaspertx.com。

前瞻性声明

本新闻稿中包含的某些陈述属于或可能被视为 1995 年《美国私人证券诉讼改革法案》所定义的“前瞻性陈述”。这些陈述的特征在于其内容并非严格限于历史或当前事实,而是在讨论未来经营或财务业绩或状况时使用诸如“估计”、“预期”、“打算”、“相信”、“计划”、“预计”、“潜在”、“预测”等词语及含义相近的其他词语和术语。Jasper 提示,这些陈述是基于 Jasper 管理层当前的看法和预期作出的,存在重大风险、不确定性和假设,包括但不限于:与本次合并交易中换股比例所隐含价值相比,Jasper 普通股市场价格相关的风险;因本次合并而产生的意外成本、费用或支出;因宣布或完成本次合并而可能引发的不利反应或业务关系变化;合并后公司候选产品所存在的不确定性,以及与候选产品临床开发和监管审批相关的风险,包括临床试验启动、入组和完成可能出现的延迟;合并后公司无法获得充足额外资金以继续推进这些候选产品及其临床前项目的相关风险;候选产品能否取得成功临床结果的不确定性,以及由此可能产生的意外成本;鉴于成功将候选产品推向市场所固有的风险和难度,正在开发及计划开发的候选产品和临床前项目可能无法实现任何价值的相关风险;本次合并预期效益(包括未来财务和经营业绩方面)可能无法实现的相关风险;私募融资未能完成的风险;CVR 持有人可能永远无法获得任何收益的可能性;Jasper 股东可能不批准优先股转换的相关风险;以及 Jasper 截至 2025 年 12 月 31 日财年的

10-K 年度报告、10-Q 季度报告及此后已提交或可能提交的 8-K 当期报告中“风险因素”部分所载的其他风险和不确定性。有关未来行动、未来业绩和/或未来结果的陈述,包括但不限于与已安排或额外临床试验完成时间及结果、FDA 或其他监管机构对合并后公司制剂和候选产品的审查和/或批准及商业化上市和销售业绩(如有)相关的陈述,以及与之相关的监管申报、财务预测和目标、业务战略、未来经营计划和目标,有关合并后公司及其经营和前景的陈述等,均可能不会发生,实际结果可能与前瞻性陈述中预期或暗示的结果存在重大不利差异。鉴于这些风险、不确定性和假设,本新闻稿中讨论的前瞻性事件和情况本质上具有不确定性,可能不会发生,实际结果可能与前瞻性陈述中预期或暗示的结果存在重大不利差异。因此,您不应将前瞻性陈述作为对未来事件的预测而加以依赖。除适用证券法可能要求外,Jasper 没有义务在本新闻稿发布之日后,因新信息、未来事件、事后发现的不准确之处或其他原因,而公开更新或修订任何前瞻性陈述,或使这些陈述与实际结果或合并后公司预期的变化保持一致。

投资者垂询

Argot Partners(投资者与媒体)

kira@argotpartners.com

Jasper Therapeutics

Alex Gray(投资者)

Jasper Therapeutics

650-549-1454

agray@jaspertx.com

媒体垂询:

media@jaspertx.com